PATH is pleased to announce that its board of directors has confirmed David P. King as board chair. Mr. King, who is chairman and CEO of LabCorp, a leading global life sciences company, has served on the PATH board since 2013.
“As a PATH board member, Dave has applied his private-sector experience to the biggest health challenges facing our world,” said Steve Davis, PATH’s president and CEO. “He is a brilliant business leader who is deeply committed to health equity, and we are delighted that he is now our board chair.”
Mr. King succeeds Dean Allen, who recently completed a three-year term as board chair.
“I’m immensely grateful to Dean for investing so much of his time and energy in our work, and for his profound commitment to PATH’s mission,” said Davis. “His insightful leadership has helped the organization to expand our network of partners around the world, opening new doors for collaboration across the public, private and nonprofit sectors.” Mr. Allen remains on PATH’s board of directors.
With Mr. King’s confirmation as board chair, other members have taken on new leadership roles. Dr. Felix Olale now serves as vice chair, Bruce McNamer will serve as treasurer, and Dr. Yehong Zhang as secretary.
“This is a pivotal moment for PATH,” said Mr. King. “It’s a time of great promise for global health, but also great uncertainty for the funding model that has sustained huge advances over the past several decades. I am committed to helping Steve Davis and his outstanding team at PATH continue to bring innovative health solutions to scale so people everywhere—and their communities and countries—can thrive.”
Before becoming CEO in 2007, he served as LabCorp’s executive vice president and chief operating officer, and prior to that he was head of the company’s US LABS/Esoterix division, one of the nation’s leading specialty testing and cancer diagnostic laboratories. Mr. King joined LabCorp in 2001 as senior vice president, general counsel, and chief compliance officer.
Before joining LabCorp, Mr. King was a partner with Hogan & Hartson, LLP (now Hogan Lovells), and prior to that he served as a federal prosecutor with the U.S. Department of Justice. He holds a bachelor’s degree, cum laude, from Princeton, and a juris doctor degree, cum laude, from the University of Pennsylvania Law School.
In addition to chairing PATH’s board of directors, Mr. King also serves on the boards of Cardinal Health, Inc., the American Clinical Laboratory Association, and the Seattle Science Foundation. He is also a trustee of Elon University in Elon, North Carolina. In 2017, he was appointed to the advisory board for Duke University’s Robert J. Margolis, MD, Center for Health Policy.
More information: PATH's board of directors.
PATH is the leader in global health innovation. An international nonprofit organization, PATH saves lives and improves health, especially among women and children. PATH accelerates innovation across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovations—that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, PATH takes innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. With these key partners, PATH delivers measurable results that disrupt the cycle of poor health. Learn more at www.path.org.
Posted February 1, 2018.